India, Oct. 29 -- Phathom Pharmaceuticals, Inc. (PHAT) reported third-quarter 2026 net revenues of $84.7 million, up 71% from $49.5 million in the prior-year quarter, driven by continued growth in prescriptions for VOQUEZNA, its treatment for gastroesophageal reflux disease (GERD).
Net loss narrowed to $13.9 million or 0.16 per share from $30.0 million or 0.41 per share a year earlier.
Non-GAAP adjusted net income was $3.0 million, compared with an adjusted net loss of $11.2 million in the prior-year period.
The company generated positive operating cash flow for the second consecutive quarter and reported cash and cash equivalents of $184.6 million as of September 30, 2026.
More than 2 million VOQUEZNA prescriptions had been filled thro...